Search

Your search keyword '"Gascoyne, Randy D."' showing total 2,586 results
Start Over Author "Gascoyne, Randy D."
2,586 results on '"Gascoyne, Randy D."'

1. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

Author

Alduaij, Waleed, Collinge, Brett, Ben-Neriah, Susana, Jiang, Aixiang, Hilton, Laura K., Boyle, Merrill, Meissner, Barbara, Chong, Lauren, Miyata-Takata, Tomoko, Slack, Graham W., Farinha, Pedro, Craig, Jeffrey W., Lytle, Andrew, Savage, Kerry J., Villa, Diego, Gerrie, Alina S., Freeman, Ciara L., Gascoyne, Randy D., Connors, Joseph M., Morin, Ryan D., Sehn, Laurie H., Mungall, Andrew J., Steidl, Christian, and Scott, David W.

Published
2023
Full Text
View/download PDF

6. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2

Author

Moffitt, Andrea B, Ondrejka, Sarah L, McKinney, Matthew, Rempel, Rachel E, Goodlad, John R, Teh, Chun Huat, Leppa, Sirpa, Mannisto, Susanna, Kovanen, Panu E, Tse, Eric, Au-Yeung, Rex KH, Kwong, Yok-Lam, Srivastava, Gopesh, Iqbal, Javeed, Yu, Jiayu, Naresh, Kikkeri, Villa, Diego, Gascoyne, Randy D, Said, Jonathan, Czader, Magdalena B, Chadburn, Amy, Richards, Kristy L, Rajagopalan, Deepthi, Davis, Nicholas S, Smith, Eileen C, Palus, Brooke C, Tzeng, Tiffany J, Healy, Jane A, Lugar, Patricia L, Datta, Jyotishka, Love, Cassandra, Levy, Shawn, Dunson, David B, Zhuang, Yuan, Hsi, Eric D, and Dave, Sandeep S

Subjects
Genetics, Cancer, Hematology, Lymphoma, Rare Diseases, Clinical Research, Biotechnology, Digestive Diseases, 2.1 Biological and endogenous factors, Aetiology, Animals, DNA Copy Number Variations, Enteropathy-Associated T-Cell Lymphoma, Female, Gene Expression Profiling, Gene Silencing, Histone-Lysine N-Methyltransferase, Humans, Male, Mice, Knockout, Middle Aged, Mutation, Sequence Analysis, DNA, T-Lymphocytes, Medical and Health Sciences, Immunology
Abstract

Enteropathy-associated T cell lymphoma (EATL) is a lethal, and the most common, neoplastic complication of celiac disease. Here, we defined the genetic landscape of EATL through whole-exome sequencing of 69 EATL tumors. SETD2 was the most frequently silenced gene in EATL (32% of cases). The JAK-STAT pathway was the most frequently mutated pathway, with frequent mutations in STAT5B as well as JAK1, JAK3, STAT3, and SOCS1 We also identified mutations in KRAS, TP53, and TERT Type I EATL and type II EATL (monomorphic epitheliotropic intestinal T cell lymphoma) had highly overlapping genetic alterations indicating shared mechanisms underlying their pathogenesis. We modeled the effects of SETD2 loss in vivo by developing a T cell-specific knockout mouse. These mice manifested an expansion of γδ T cells, indicating novel roles for SETD2 in T cell development and lymphomagenesis. Our data render the most comprehensive genetic portrait yet of this uncommon but lethal disease and may inform future classification schemes.

Published
2017

7. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

Author

Jiang, Yanwen, Ortega-Molina, Ana, Geng, Huimin, Ying, Hsia-Yuan, Hatzi, Katerina, Parsa, Sara, McNally, Dylan, Wang, Ling, Doane, Ashley S, Agirre, Xabier, Teater, Matt, Meydan, Cem, Li, Zhuoning, Poloway, David, Wang, Shenqiu, Ennishi, Daisuke, Scott, David W, Stengel, Kristy R, Kranz, Janice E, Holson, Edward, Sharma, Sneh, Young, James W, Chu, Chi-Shuen, Roeder, Robert G, Shaknovich, Rita, Hiebert, Scott W, Gascoyne, Randy D, Tam, Wayne, Elemento, Olivier, Wendel, Hans-Guido, and Melnick, Ari M

Subjects
Hematology, Rare Diseases, Lymphoma, Genetics, Clinical Research, Cancer, Biotechnology, Aetiology, 2.1 Biological and endogenous factors, Acetylation, Animals, CREB-Binding Protein, Cell Line, Tumor, Enhancer Elements, Genetic, Gene Knockout Techniques, Germinal Center, Histone Deacetylases, Histones, Humans, Lymphoma, Large B-Cell, Diffuse, Mice, Mutation, Neoplasm Transplantation, Nuclear Receptor Co-Repressor 2, Proto-Oncogene Proteins c-bcl-6, Transcription, Genetic, Oncology and Carcinogenesis
Abstract

Somatic mutations in CREBBP occur frequently in B-cell lymphoma. Here, we show that loss of CREBBP facilitates the development of germinal center (GC)-derived lymphomas in mice. In both human and murine lymphomas, CREBBP loss-of-function resulted in focal depletion of enhancer H3K27 acetylation and aberrant transcriptional silencing of genes that regulate B-cell signaling and immune responses, including class II MHC. Mechanistically, CREBBP-regulated enhancers are counter-regulated by the BCL6 transcriptional repressor in a complex with SMRT and HDAC3, which we found to bind extensively to MHC class II loci. HDAC3 loss-of-function rescued repression of these enhancers and corresponding genes, including MHC class II, and more profoundly suppressed CREBBP-mutant lymphomas in vitro and in vivo Hence, CREBBP loss-of-function contributes to lymphomagenesis by enabling unopposed suppression of enhancers by BCL6/SMRT/HDAC3 complexes, suggesting HDAC3-targeted therapy as a precision approach for CREBBP-mutant lymphomas.SignificanceOur findings establish the tumor suppressor function of CREBBP in GC lymphomas in which CREBBP mutations disable acetylation and result in unopposed deacetylation by BCL6/SMRT/HDAC3 complexes at enhancers of B-cell signaling and immune response genes. Hence, inhibition of HDAC3 can restore the enhancer histone acetylation and may serve as a targeted therapy for CREBBP-mutant lymphomas. Cancer Discov; 7(1); 38-53. ©2016 AACR.See related commentary by Höpken, p. 14This article is highlighted in the In This Issue feature, p. 1.

Published
2017

8. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis

Author

Béguelin, Wendy, Teater, Matt, Gearhart, Micah D, Fernández, María Teresa Calvo, Goldstein, Rebecca L, Cárdenas, Mariano G, Hatzi, Katerina, Rosen, Monica, Shen, Hao, Corcoran, Connie M, Hamline, Michelle Y, Gascoyne, Randy D, Levine, Ross L, Abdel-Wahab, Omar, Licht, Jonathan D, Shaknovich, Rita, Elemento, Olivier, Bardwell, Vivian J, and Melnick, Ari M

Subjects
Rare Diseases, Genetics, Hematology, Lymphoma, Cancer, Animals, Enhancer of Zeste Homolog 2 Protein, Germinal Center, Humans, Lymphoma, Large B-Cell, Diffuse, Mice, Mice, Inbred C57BL, Mice, Transgenic, Mitochondrial Membrane Transport Proteins, Polycomb Repressive Complex 1, Polycomb-Group Proteins, Promoter Regions, Genetic, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-bcl-6, Repressor Proteins, Transcription, Genetic, Neurosciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

The EZH2 histone methyltransferase mediates the humoral immune response and drives lymphomagenesis through formation of bivalent chromatin domains at critical germinal center (GC) B cell promoters. Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex. The chromodomain protein CBX8 is induced in GC B cells, binds to H3K27me3 at bivalent promoters, and is required for stable association of the complex and the resulting histone modifications. Moreover, oncogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and combinatorial targeting of these repressors results in enhanced anti-lymphoma activity in DLBCLs.

Published
2016

9. Role of the tumor microenvironment in mature B-cell lymphoid malignancies

Author

Fowler, Nathan H, Cheah, Chan Yoon, Gascoyne, Randy D, Gribben, John, Neelapu, Sattva S, Ghia, Paolo, Bollard, Catherine, Ansell, Stephen, Curran, Michael, Wilson, Wyndham H, O'Brien, Susan, Grant, Cliona, Little, Richard, Zenz, Thorsten, Nastoupil, Loretta J, and Dunleavy, Kieron

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Hematology, Rare Diseases, Cancer, Lymphoma, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system, Animals, B-Lymphocytes, Biomarkers, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Humans, Immunotherapy, Leukemia, B-Cell, Lymphoma, B-Cell, Molecular Targeted Therapy, Neoplasm Grading, Neoplasm Staging, Signal Transduction, Tumor Escape, Tumor Microenvironment, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

The tumor microenvironment is the cellular and molecular environment in which the tumor exists and with which it continuously interacts. In B-cell lymphomas, this microenvironment is intriguing in that it plays critical roles in the regulation of tumor cell survival and proliferation, fostering immune escape as well as the development of treatment resistance. The purpose of this review is to summarize the proceedings of the Second Annual Summit on the Immune Microenvironment in Hematologic Malignancies that took place on September 11-12, 2014 in Dublin, Ireland. We provide a timely overview of the composition and biological relevance of the cellular and molecular microenvironment interface and discuss the role of interactions between the microenvironment and neoplastic cells in a variety of B-cell lymphomas. In addition, we focus on various novel therapeutic strategies that target the tumor microenvironment, including agents that modulate B-cell receptor pathways and immune-checkpoints, chimeric antigen receptor T cells and immunomodulatory agents.

Published
2016

10. Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era

Author

Diefenbach, Catherine S, Li, Hailun, Hong, Fangxin, Gordon, Leo I, Fisher, Richard I, Bartlett, Nancy L, Crump, Michael, Gascoyne, Randy D, Wagner, Henry, Stiff, Patrick J, Cheson, Bruce D, Stewart, Douglas A, Kahl, Brad S, Friedberg, Jonathan W, Blum, Kristie A, Habermann, Thomas M, Tuscano, Joseph M, Hoppe, Richard T, Horning, Sandra J, and Advani, Ranjana H

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Patient Safety, Hematology, Clinical Research, Lymphoma, Cancer, Rare Diseases, Age Factors, Antineoplastic Combined Chemotherapy Protocols, Area Under Curve, Bleomycin, Clinical Trials, Phase III as Topic, Dacarbazine, Disease-Free Survival, Doxorubicin, Etoposide, Hodgkin Disease, Humans, Kaplan-Meier Estimate, Mechlorethamine, Multicenter Studies as Topic, Prednisone, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Sample Size, Severity of Illness Index, Survival Analysis, Vinblastine, Vincristine, ABVD, Hodgkin lymphoma, International Prognostic Score, Stanford V, prognostic score, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

The International Prognostic Score (IPS-7) is the most commonly used risk stratification tool for advanced Hodgkin lymphoma (HL), however recent studies suggest the IPS-7 is less discriminating due to improved outcomes with contemporary therapy. We evaluated the seven variables for IPS-7 recorded at study entry for 854 patients enrolled on Eastern Cooperative Oncology Group 2496 trial. Univariate and multivariate Cox models were used to assess their prognostic ability for freedom from progression (FFP) and overall survival (OS). The IPS-7 remained prognostic however its prognostic range has narrowed. On multivariate analysis, two factors (age, stage) remained significant for FFP and three factors (age, stage, haemoglobin level) for OS. An alternative prognostic index, the IPS-3, was constructed using age, stage and haemoglobin level, which provided four distinct risk groups [FFP (P = 0·0001) and OS (P

Published
2015

12. The whole-genome landscape of Burkitt lymphoma subtypes

Author

Panea, Razvan I., Love, Cassandra L., Shingleton, Jennifer R., Reddy, Anupama, Bailey, Jeffrey A., Moormann, Ann M., Otieno, Juliana A., Ong'echa, John Michael, Oduor, Cliff I., Schroeder, Kristin M.S., Masalu, Nestory, Chao, Nelson J., Agajanian, Megan, Major, Michael B., Fedoriw, Yuri, Richards, Kristy L., Rymkiewicz, Grzegorz, Miles, Rodney R., Alobeid, Bachir, Bhagat, Govind, Flowers, Christopher R., Ondrejka, Sarah L., Hsi, Eric D., Choi, William W.L., Au-Yeung, Rex K.H., Hartmann, Wolfgang, Lenz, Georg, Meyerson, Howard, Lin, Yen-Yu, Zhuang, Yuan, Luftig, Micah A., Waldrop, Alexander, Dave, Tushar, Thakkar, Devang, Sahay, Harshit, Li, Guojie, Palus, Brooke C., Seshadri, Vidya, Kim, So Young, Gascoyne, Randy D., Levy, Shawn, Mukhopadyay, Minerva, Dunson, David B., and Dave, Sandeep S.

Published
2019
Full Text
View/download PDF

13. TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

Author

Ennishi, Daisuke, Healy, Shannon, Bashashati, Ali, Saberi, Saeed, Hother, Christoffer, Mottok, Anja, Chan, Fong Chun, Chong, Lauren, Abraham, Libin, Kridel, Robert, Boyle, Merrill, Meissner, Barbara, Aoki, Tomohiro, Takata, Katsuyoshi, Woolcock, Bruce W., Viganò, Elena, Gold, Michael, Molday, Laurie L., Molday, Robert S., Telenius, Adele, Li, Michael Y., Wretham, Nicole, Dos Santos, Nancy, Wong, Mark, Viller, Natasja N., Uger, Robert A., Duns, Gerben, Baticados, Abigail, Madero, Angel, Bristow, Brianna N., Farinha, Pedro, Slack, Graham W., Ben-Neriah, Susana, Lai, Daniel, Zhang, Allen W., Salehi, Sohrab, Shulha, Hennady P., Chiu, Derek S., Mostafavi, Sara, Gerrie, Alina S., Huang, Da Wei, Rushton, Christopher, Villa, Diego, Sehn, Laurie H., Savage, Kerry J., Mungall, Andrew J., Weng, Andrew P., Bally, Marcel B., Morin, Ryan D., Cohen Freue, Gabriela V., Staudt, Louis M., Connors, Joseph M., Marra, Marco A., Shah, Sohrab P., Gascoyne, Randy D., Scott, David W., and Steidl, Christian

Published
2020
Full Text
View/download PDF

14. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial

Author

Advani, Ranjana H, Hong, Fangxin, Fisher, Richard I, Bartlett, Nancy L, Robinson, K Sue, Gascoyne, Randy D, Wagner, Henry, Stiff, Patrick J, Cheson, Bruce D, Stewart, Douglas A, Gordon, Leo I, Kahl, Brad S, Friedberg, Jonathan W, Blum, Kristie A, Habermann, Thomas M, Tuscano, Joseph M, Hoppe, Richard T, and Horning, Sandra J

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Hematology, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Chemotherapy, Adjuvant, Cyclophosphamide, Dacarbazine, Disease-Free Survival, Doxorubicin, Etoposide, Female, Hodgkin Disease, Humans, Kaplan-Meier Estimate, Male, Mechlorethamine, Mediastinal Neoplasms, Middle Aged, Neoplasm Staging, North America, Prednisone, Procarbazine, Radiotherapy, Adjuvant, Risk Factors, Treatment Outcome, Vinblastine, Vincristine, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThe phase III North American Intergroup E2496 Trial (Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma) compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with mechlorethamine, doxorubicin, vincristine, bleomycin, vinblastine, etoposide, and prednisone (Stanford V). We report results of a planned subgroup analysis in patients with stage I or II bulky mediastinal Hodgkin lymphoma (HL).Patients and methodsPatients were randomly assigned to six to eight cycles of ABVD every 28 days or Stanford V once per week for 12 weeks. Two to 3 weeks after completion of chemotherapy, all patients received 36 Gy of modified involved field radiotherapy (IFRT) to the mediastinum, hila, and supraclavicular regions. Patients on the Stanford V arm received IFRT to additional sites ≥ 5 cm at diagnosis. Primary end points were failure-free survival (FFS) and overall survival (OS).ResultsOf 794 eligible patients, 264 had stage I or II bulky disease, 135 received ABVD, and 129 received Stanford V. Patient characteristics were matched. The overall response rate was 83% with ABVD and 88% with Stanford V. At a median follow-up of 6.5 years, the study excluded a difference of more than 21% in 5-year FFS and more than 16% in 5-year OS between ABVD and Stanford V (5-year FFS: 85% v 79%; HR, 0.68; 95% CI, 0.37 to 1.25; P = .22; 5-year OS: 96% v 92%; HR, 0.49; 95% CI, 0.16 to 1.47; P = .19). In-field relapses occurred in < 10% of the patients in each arm.ConclusionFor patients with stage I or II bulky mediastinal HL, no substantial statistically significant differences were detected between the two regimens, although power was limited. To the best of our knowledge, this is the first prospective trial reporting outcomes specific to this subgroup, and it sets a benchmark for comparison of ongoing and future studies.

Published
2015

15. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

Author

Mottok, Anja, Hung, Stacy S., Chavez, Elizabeth A., Woolcock, Bruce, Telenius, Adèle, Chong, Lauren C., Meissner, Barbara, Nakamura, Hisae, Rushton, Christopher, Viganò, Elena, Sarkozy, Clementine, Gascoyne, Randy D., Connors, Joseph M., Ben-Neriah, Susana, Mungall, Andrew, Marra, Marco A., Siebert, Reiner, Scott, David W., Savage, Kerry J., and Steidl, Christian

Published
2019
Full Text
View/download PDF

16. Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma

Author

Takata, Katsuyoshi, Chong, Lauren C., Ennishi, Daisuke, Aoki, Tomohiro, Li, Michael Yu, Thakur, Avinash, Healy, Shannon, Vigano, Elena, Dao, Tao, Kwon, Daniel, Duns, Gerben, Nielsen, Julie S., Ben-Neriah, Susana, Tse, Ethan, Hung, Stacy S., Boyle, Merrill, Mun, Sung Soo, Bourne, Christopher M., Woolcock, Bruce, Telenius, Adele, Kishida, Makoto, Rai, Shinya, Zhang, Allen W., Bashashati, Ali, Saberi, Saeed, DAntonio, Gianluca, Nelson, Brad H., Shah, Sohrab P., Hoodless, Pamela A., Melnick, Ari M., Gascoyne, Randy D., Connors, Joseph M., Scheinberg, David A., Beguelin, Wendy, Scott, David W., and Steidl, Christian

Subjects
Oncology, Experimental, Gene mutations -- Research, Immune response -- Genetic aspects, Non-Hodgkin's lymphomas -- Genetic aspects -- Care and treatment, Tumor antigens -- Genetic aspects, Cancer -- Research, Health care industry
Abstract

PRAME is a prominent member of the cancer testis antigen family of proteins, which triggers autologous T cell-mediated immune responses. Integrative genomic analysis in diffuse large B cell lymphoma (DLBCL) uncovered recurrent and highly focal deletions of 22q11.22, including the PRAME gene, which were associated with poor outcome. PRAME-deleted tumors showed cytotoxic T cell immune escape and were associated with cold tumor microenvironments. In addition, PRAME downmodulation was strongly associated with somatic EZH2 Y641 mutations in DLBCL. In turn, PRC2-regulated genes were repressed in isogenic PRAME-KO lymphoma cell lines, and PRAME was found to directly interact with EZH2 as a negative regulator. EZH2 inhibition with EPZ-6438 abrogated these extrinsic and intrinsic effects, leading to PRAME expression and microenvironment restoration in vivo. Our data highlight multiple functions of PRAME during lymphomagenesis and provide a preclinical rationale for synergistic therapies combining epigenetic reprogramming with PRAME-targeted therapies., Introduction The current treatment standard of combined immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has achieved significant improvement in patient outcomes in diffuse large B cell lymphoma (DLBCL) [...]

Published
2022
Full Text
View/download PDF

17. Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas

Author

Hsi, Eric D, Said, Jonathan, Macon, William R, Rodig, Scott J, Ondrejka, Sarah L, Gascoyne, Randy D, Morgan, Elizabeth A, Dorfman, David M, Maurer, Matthew J, and Dogan, Ahmet

Subjects
Hematology, Clinical Research, Rare Diseases, Cancer, Lymphoma, Algorithms, Biomarkers, Tumor, Gene Rearrangement, Genetic Predisposition to Disease, Humans, Immunohistochemistry, Immunophenotyping, Kaplan-Meier Estimate, Lymphoma, Extranodal NK-T-Cell, Lymphoma, T-Cell, Peripheral, Molecular Diagnostic Techniques, North America, Phenotype, Predictive Value of Tests, Prognosis, Retrospective Studies, peripheral T-cell lymphoma, diagnosis, accuracy, evidence-based medicine, pathology, guidelines, Clinical Sciences, Pathology
Abstract

The diagnosis of peripheral T-cell and NK-cell lymphomas (PTNKCL) is difficult with few standards for required ancillary studies. We evaluated a series of PTNKCLs using a tiered approach to immunohistochemistry and molecular genetic characterization to document diagnostic accuracy and clinical relevance. Seven hematopathologists reviewed 374 cases that included PTNKCL and non-PTNKCL cases to mimic diagnostic practice. Cases received tier 0, 1, and 2 diagnoses by 3 independent pathologists, on the basis of hematoxylin and eosin stains and progressive immunohistochemistry panels. A tier 2b diagnosis was rendered when gene rearrangement data were available, and a final consensus diagnosis was rendered after discussion of each case. Across all 374 cases, consensus agreement was 92.5%. For PTNKCLs, World Health Organization subclassification was possible in 16.5%, 37.1%, 82.8%, and 85.9% of individual reviewer diagnoses at tier 0, 1, 2, and 2b, respectively. Gene rearrangement contributed to a change in diagnosis in 51 of 647 (8%) individual reviews. Following this algorithm may provide prognostic information on the basis of individual marker expression in common PTNKCL types (CD4 in peripheral T-cell lymphoma, not otherwise specified and PD-1 in angioimmunoblastic T-cell lymphoma). This evidence-based approach to the diagnosis of PTNKCL informs practicing pathologists, clinical trial designers, and policy-makers regarding required ancillary studies.

Published
2014

18. Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles

Author

Hellmuth, Johannes C., Louissaint, Abner, Jr, Szczepanowski, Monika, Haebe, Sarah, Pastore, Alessandro, Alig, Stefan, Staiger, Annette M., Hartmann, Sylvia, Kridel, Robert, Ducar, Matthew D., Koch, Peter, Dreyling, Martin, Hansmann, Martin-Leo, Ott, German, Rosenwald, Andreas, Gascoyne, Randy D., Weinstock, David M., Hiddemann, Wolfgang, Klapper, Wolfram, and Weigert, Oliver

Published
2018
Full Text
View/download PDF

19. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome

Author

Clot, Guillem, Jares, Pedro, Giné, Eva, Navarro, Alba, Royo, Cristina, Pinyol, Magda, Martín-Garcia, David, Demajo, Santiago, Espinet, Blanca, Salar, Antonio, Ferrer, Ana, Muntañola, Ana, Aymerich, Marta, Rauert-Wunderlich, Hilka, Jaffe, Elaine S., Connors, Joseph M., Gascoyne, Randy D., Delabie, Jan, López-Guillermo, Armando, Ott, German, Wright, George W., Staudt, Louis M., Rosenwald, Andreas, Scott, David W., Rimsza, Lisa M., Beà, Sílvia, and Campo, Elías

Published
2018
Full Text
View/download PDF

21. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death

Author

Clark, Mary C, Pang, Mabel, Hsu, Daniel K, Liu, Fu-Tong, de Vos, Sven, Gascoyne, Randy D, Said, Jonathan, and Baum, Linda G

Subjects
Hematology, Rare Diseases, Lymphoma, Cancer, Aetiology, 2.1 Biological and endogenous factors, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Apoptosis, Cell Line, Tumor, Cell Membrane, Cell Survival, Dexamethasone, Dose-Response Relationship, Drug, Etoposide, Flow Cytometry, Galectin 3, Glycosylation, Humans, Immunoblotting, Immunohistochemistry, Leukocyte Common Antigens, Lymphoma, Large B-Cell, Diffuse, N-Acetylglucosaminyltransferases, Polysaccharides, Protein Binding, RNA Interference, Rituximab, Tissue Array Analysis, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology
Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and an aggressive malignancy. Galectin-3 (gal-3), the only antiapoptotic member of the galectin family, is overexpressed in DLBCL. While gal-3 can localize to intracellular sites, gal-3 is secreted by DLBCL cells and binds back to the cell surface in a carbohydrate-dependent manner. The major counterreceptor for gal-3 on DLBCL cells was identified as the transmembrane tyrosine phosphatase CD45. Removal of cell-surface gal-3 from CD45 with the polyvalent glycan inhibitor GCS-100 rendered DLBCL cells susceptible to chemotherapeutic agents. Binding of gal-3 to CD45 modulated tyrosine phosphatase activity; removal of endogenous cell-surface gal-3 from CD45 with GCS-100 increased phosphatase activity, while addition of exogenous gal-3 reduced phosphatase activity. Moreover, the increased susceptibility of DLBCL cells to chemotherapeutic agents after removal of gal-3 by GCS-100 required CD45 phosphatase activity. Gal-3 binding to a subset of highly glycosylated CD45 glycoforms was regulated by the C2GnT-1 glycosyltransferase, indicating that specific glycosylation of CD45 is important for regulation of gal-3-mediated signaling. These data identify a novel role for cell-surface gal-3 and CD45 in DLBCL survival and suggest novel therapeutic targets to sensitize DLBCL cells to death.

Published
2012

22. Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Author

Bouska, Alyssa, Bi, Chengfeng, Lone, Waseem, Zhang, Weiwei, Kedwaii, Ambreen, Heavican, Tayla, Lachel, Cynthia M., Yu, Jiayu, Ferro, Roberto, Eldorghamy, Nanees, Greiner, Timothy C., Vose, Julie, Weisenburger, Dennis D., Gascoyne, Randy D., Rosenwald, Andreas, Ott, German, Campo, Elias, Rimsza, Lisa M., Jaffe, Elaine S., Braziel, Rita M., Siebert, Reiner, Miles, Rodney R., Dave, Sandeep, Reddy, Anupama, Delabie, Jan, Staudt, Louis M., Song, Joo Y., McKeithan, Timothy W., Fu, Kai, Green, Michael, Chan, Wing C., and Iqbal, Javeed

Published
2017
Full Text
View/download PDF

23. Data from The Genetic Basis of Hepatosplenic T-cell Lymphoma

Author

McKinney, Matthew, primary, Moffitt, Andrea B., primary, Gaulard, Philippe, primary, Travert, Marion, primary, De Leval, Laurence, primary, Nicolae, Alina, primary, Raffeld, Mark, primary, Jaffe, Elaine S., primary, Pittaluga, Stefania, primary, Xi, Liqiang, primary, Heavican, Tayla, primary, Iqbal, Javeed, primary, Belhadj, Karim, primary, Delfau-Larue, Marie Helene, primary, Fataccioli, Virginie, primary, Czader, Magdalena B., primary, Lossos, Izidore S., primary, Chapman-Fredricks, Jennifer R., primary, Richards, Kristy L., primary, Fedoriw, Yuri, primary, Ondrejka, Sarah L., primary, Hsi, Eric D., primary, Low, Lawrence, primary, Weisenburger, Dennis, primary, Chan, Wing C., primary, Mehta-Shah, Neha, primary, Horwitz, Steven, primary, Bernal-Mizrachi, Leon, primary, Flowers, Christopher R., primary, Beaven, Anne W., primary, Parihar, Mayur, primary, Baseggio, Lucile, primary, Parrens, Marie, primary, Moreau, Anne, primary, Sujobert, Pierre, primary, Pilichowska, Monika, primary, Evens, Andrew M., primary, Chadburn, Amy, primary, Au-Yeung, Rex K.H., primary, Srivastava, Gopesh, primary, Choi, William W. L., primary, Goodlad, John R., primary, Aurer, Igor, primary, Basic-Kinda, Sandra, primary, Gascoyne, Randy D., primary, Davis, Nicholas S., primary, Li, Guojie, primary, Zhang, Jenny, primary, Rajagopalan, Deepthi, primary, Reddy, Anupama, primary, Love, Cassandra, primary, Levy, Shawn, primary, Zhuang, Yuan, primary, Datta, Jyotishka, primary, Dunson, David B., primary, and Davé, Sandeep S., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table S11 and 15 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

Author

Ennishi, Daisuke, primary, Takata, Katsuyoshi, primary, Béguelin, Wendy, primary, Duns, Gerben, primary, Mottok, Anja, primary, Farinha, Pedro, primary, Bashashati, Ali, primary, Saberi, Saeed, primary, Boyle, Merrill, primary, Meissner, Barbara, primary, Ben-Neriah, Susana, primary, Woolcock, Bruce W., primary, Telenius, Adèle, primary, Lai, Daniel, primary, Teater, Matt, primary, Kridel, Robert, primary, Savage, Kerry J., primary, Sehn, Laurie H., primary, Morin, Ryan D., primary, Marra, Marco A., primary, Shah, Sohrab P., primary, Connors, Joseph M., primary, Gascoyne, Randy D., primary, Scott, David W., primary, Melnick, Ari M., primary, and Steidl, Christian, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

Author

Ennishi, Daisuke, primary, Takata, Katsuyoshi, primary, Béguelin, Wendy, primary, Duns, Gerben, primary, Mottok, Anja, primary, Farinha, Pedro, primary, Bashashati, Ali, primary, Saberi, Saeed, primary, Boyle, Merrill, primary, Meissner, Barbara, primary, Ben-Neriah, Susana, primary, Woolcock, Bruce W., primary, Telenius, Adèle, primary, Lai, Daniel, primary, Teater, Matt, primary, Kridel, Robert, primary, Savage, Kerry J., primary, Sehn, Laurie H., primary, Morin, Ryan D., primary, Marra, Marco A., primary, Shah, Sohrab P., primary, Connors, Joseph M., primary, Gascoyne, Randy D., primary, Scott, David W., primary, Melnick, Ari M., primary, and Steidl, Christian, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table S8-9 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

Author

Ennishi, Daisuke, primary, Takata, Katsuyoshi, primary, Béguelin, Wendy, primary, Duns, Gerben, primary, Mottok, Anja, primary, Farinha, Pedro, primary, Bashashati, Ali, primary, Saberi, Saeed, primary, Boyle, Merrill, primary, Meissner, Barbara, primary, Ben-Neriah, Susana, primary, Woolcock, Bruce W., primary, Telenius, Adèle, primary, Lai, Daniel, primary, Teater, Matt, primary, Kridel, Robert, primary, Savage, Kerry J., primary, Sehn, Laurie H., primary, Morin, Ryan D., primary, Marra, Marco A., primary, Shah, Sohrab P., primary, Connors, Joseph M., primary, Gascoyne, Randy D., primary, Scott, David W., primary, Melnick, Ari M., primary, and Steidl, Christian, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table S12-14 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

Author

Ennishi, Daisuke, primary, Takata, Katsuyoshi, primary, Béguelin, Wendy, primary, Duns, Gerben, primary, Mottok, Anja, primary, Farinha, Pedro, primary, Bashashati, Ali, primary, Saberi, Saeed, primary, Boyle, Merrill, primary, Meissner, Barbara, primary, Ben-Neriah, Susana, primary, Woolcock, Bruce W., primary, Telenius, Adèle, primary, Lai, Daniel, primary, Teater, Matt, primary, Kridel, Robert, primary, Savage, Kerry J., primary, Sehn, Laurie H., primary, Morin, Ryan D., primary, Marra, Marco A., primary, Shah, Sohrab P., primary, Connors, Joseph M., primary, Gascoyne, Randy D., primary, Scott, David W., primary, Melnick, Ari M., primary, and Steidl, Christian, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table S5 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

Author

Jiang, Yanwen, primary, Ortega-Molina, Ana, primary, Geng, Huimin, primary, Ying, Hsia-Yuan, primary, Hatzi, Katerina, primary, Parsa, Sara, primary, McNally, Dylan, primary, Wang, Ling, primary, Doane, Ashley S., primary, Agirre, Xabier, primary, Teater, Matt, primary, Meydan, Cem, primary, Li, Zhuoning, primary, Poloway, David, primary, Wang, Shenqiu, primary, Ennishi, Daisuke, primary, Scott, David W., primary, Stengel, Kristy R., primary, Kranz, Janice E., primary, Holson, Edward, primary, Sharma, Sneh, primary, Young, James W., primary, Chu, Chi-Shuen, primary, Roeder, Robert G., primary, Shaknovich, Rita, primary, Hiebert, Scott W., primary, Gascoyne, Randy D., primary, Tam, Wayne, primary, Elemento, Olivier, primary, Wendel, Hans-Guido, primary, and Melnick, Ari M., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Tables S1 - S10 from The Genetic Basis of Hepatosplenic T-cell Lymphoma

Author

McKinney, Matthew, primary, Moffitt, Andrea B., primary, Gaulard, Philippe, primary, Travert, Marion, primary, De Leval, Laurence, primary, Nicolae, Alina, primary, Raffeld, Mark, primary, Jaffe, Elaine S., primary, Pittaluga, Stefania, primary, Xi, Liqiang, primary, Heavican, Tayla, primary, Iqbal, Javeed, primary, Belhadj, Karim, primary, Delfau-Larue, Marie Helene, primary, Fataccioli, Virginie, primary, Czader, Magdalena B., primary, Lossos, Izidore S., primary, Chapman-Fredricks, Jennifer R., primary, Richards, Kristy L., primary, Fedoriw, Yuri, primary, Ondrejka, Sarah L., primary, Hsi, Eric D., primary, Low, Lawrence, primary, Weisenburger, Dennis, primary, Chan, Wing C., primary, Mehta-Shah, Neha, primary, Horwitz, Steven, primary, Bernal-Mizrachi, Leon, primary, Flowers, Christopher R., primary, Beaven, Anne W., primary, Parihar, Mayur, primary, Baseggio, Lucile, primary, Parrens, Marie, primary, Moreau, Anne, primary, Sujobert, Pierre, primary, Pilichowska, Monika, primary, Evens, Andrew M., primary, Chadburn, Amy, primary, Au-Yeung, Rex K.H., primary, Srivastava, Gopesh, primary, Choi, William W. L., primary, Goodlad, John R., primary, Aurer, Igor, primary, Basic-Kinda, Sandra, primary, Gascoyne, Randy D., primary, Davis, Nicholas S., primary, Li, Guojie, primary, Zhang, Jenny, primary, Rajagopalan, Deepthi, primary, Reddy, Anupama, primary, Love, Cassandra, primary, Levy, Shawn, primary, Zhuang, Yuan, primary, Datta, Jyotishka, primary, Dunson, David B., primary, and Davé, Sandeep S., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Methods, Figures S1 - S9 from The Genetic Basis of Hepatosplenic T-cell Lymphoma

Author

McKinney, Matthew, primary, Moffitt, Andrea B., primary, Gaulard, Philippe, primary, Travert, Marion, primary, De Leval, Laurence, primary, Nicolae, Alina, primary, Raffeld, Mark, primary, Jaffe, Elaine S., primary, Pittaluga, Stefania, primary, Xi, Liqiang, primary, Heavican, Tayla, primary, Iqbal, Javeed, primary, Belhadj, Karim, primary, Delfau-Larue, Marie Helene, primary, Fataccioli, Virginie, primary, Czader, Magdalena B., primary, Lossos, Izidore S., primary, Chapman-Fredricks, Jennifer R., primary, Richards, Kristy L., primary, Fedoriw, Yuri, primary, Ondrejka, Sarah L., primary, Hsi, Eric D., primary, Low, Lawrence, primary, Weisenburger, Dennis, primary, Chan, Wing C., primary, Mehta-Shah, Neha, primary, Horwitz, Steven, primary, Bernal-Mizrachi, Leon, primary, Flowers, Christopher R., primary, Beaven, Anne W., primary, Parihar, Mayur, primary, Baseggio, Lucile, primary, Parrens, Marie, primary, Moreau, Anne, primary, Sujobert, Pierre, primary, Pilichowska, Monika, primary, Evens, Andrew M., primary, Chadburn, Amy, primary, Au-Yeung, Rex K.H., primary, Srivastava, Gopesh, primary, Choi, William W. L., primary, Goodlad, John R., primary, Aurer, Igor, primary, Basic-Kinda, Sandra, primary, Gascoyne, Randy D., primary, Davis, Nicholas S., primary, Li, Guojie, primary, Zhang, Jenny, primary, Rajagopalan, Deepthi, primary, Reddy, Anupama, primary, Love, Cassandra, primary, Levy, Shawn, primary, Zhuang, Yuan, primary, Datta, Jyotishka, primary, Dunson, David B., primary, and Davé, Sandeep S., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Fig. 3 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

Author

Yang, Yibin, primary, Schmitz, Roland, primary, Mitala, Joseph, primary, Whiting, Amanda, primary, Xiao, Wenming, primary, Ceribelli, Michele, primary, Wright, George W., primary, Zhao, Hong, primary, Yang, Yandan, primary, Xu, Weihong, primary, Rosenwald, Andreas, primary, Ott, German, primary, Gascoyne, Randy D., primary, Connors, Joseph M., primary, Rimsza, Lisa M., primary, Campo, Elias, primary, Jaffe, Elaine S., primary, Delabie, Jan, primary, Smeland, Erlend B., primary, Braziel, Rita M., primary, Tubbs, Raymond R., primary, Cook, James R., primary, Weisenburger, Dennis D., primary, Chan, Wing C., primary, Wiestner, Adrian, primary, Kruhlak, Michael J., primary, Iwai, Kazuhiro, primary, Bernal, Federico, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

32. Data from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

Author

Jiang, Yanwen, primary, Ortega-Molina, Ana, primary, Geng, Huimin, primary, Ying, Hsia-Yuan, primary, Hatzi, Katerina, primary, Parsa, Sara, primary, McNally, Dylan, primary, Wang, Ling, primary, Doane, Ashley S., primary, Agirre, Xabier, primary, Teater, Matt, primary, Meydan, Cem, primary, Li, Zhuoning, primary, Poloway, David, primary, Wang, Shenqiu, primary, Ennishi, Daisuke, primary, Scott, David W., primary, Stengel, Kristy R., primary, Kranz, Janice E., primary, Holson, Edward, primary, Sharma, Sneh, primary, Young, James W., primary, Chu, Chi-Shuen, primary, Roeder, Robert G., primary, Shaknovich, Rita, primary, Hiebert, Scott W., primary, Gascoyne, Randy D., primary, Tam, Wayne, primary, Elemento, Olivier, primary, Wendel, Hans-Guido, primary, and Melnick, Ari M., primary

Published
2023
Full Text
View/download PDF

33. Figures S7 - S9 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Fig. 2 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

Author

Yang, Yibin, primary, Schmitz, Roland, primary, Mitala, Joseph, primary, Whiting, Amanda, primary, Xiao, Wenming, primary, Ceribelli, Michele, primary, Wright, George W., primary, Zhao, Hong, primary, Yang, Yandan, primary, Xu, Weihong, primary, Rosenwald, Andreas, primary, Ott, German, primary, Gascoyne, Randy D., primary, Connors, Joseph M., primary, Rimsza, Lisa M., primary, Campo, Elias, primary, Jaffe, Elaine S., primary, Delabie, Jan, primary, Smeland, Erlend B., primary, Braziel, Rita M., primary, Tubbs, Raymond R., primary, Cook, James R., primary, Weisenburger, Dennis D., primary, Chan, Wing C., primary, Wiestner, Adrian, primary, Kruhlak, Michael J., primary, Iwai, Kazuhiro, primary, Bernal, Federico, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

35. Figure S5 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 2 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

Author

Yang, Yibin, primary, Schmitz, Roland, primary, Mitala, Joseph, primary, Whiting, Amanda, primary, Xiao, Wenming, primary, Ceribelli, Michele, primary, Wright, George W., primary, Zhao, Hong, primary, Yang, Yandan, primary, Xu, Weihong, primary, Rosenwald, Andreas, primary, Ott, German, primary, Gascoyne, Randy D., primary, Connors, Joseph M., primary, Rimsza, Lisa M., primary, Campo, Elias, primary, Jaffe, Elaine S., primary, Delabie, Jan, primary, Smeland, Erlend B., primary, Braziel, Rita M., primary, Tubbs, Raymond R., primary, Cook, James R., primary, Weisenburger, Dennis D., primary, Chan, Wing C., primary, Wiestner, Adrian, primary, Kruhlak, Michael J., primary, Iwai, Kazuhiro, primary, Bernal, Federico, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Fig. 5 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

Author

Yang, Yibin, primary, Schmitz, Roland, primary, Mitala, Joseph, primary, Whiting, Amanda, primary, Xiao, Wenming, primary, Ceribelli, Michele, primary, Wright, George W., primary, Zhao, Hong, primary, Yang, Yandan, primary, Xu, Weihong, primary, Rosenwald, Andreas, primary, Ott, German, primary, Gascoyne, Randy D., primary, Connors, Joseph M., primary, Rimsza, Lisa M., primary, Campo, Elias, primary, Jaffe, Elaine S., primary, Delabie, Jan, primary, Smeland, Erlend B., primary, Braziel, Rita M., primary, Tubbs, Raymond R., primary, Cook, James R., primary, Weisenburger, Dennis D., primary, Chan, Wing C., primary, Wiestner, Adrian, primary, Kruhlak, Michael J., primary, Iwai, Kazuhiro, primary, Bernal, Federico, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Fig. 4 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

Author

Yang, Yibin, primary, Schmitz, Roland, primary, Mitala, Joseph, primary, Whiting, Amanda, primary, Xiao, Wenming, primary, Ceribelli, Michele, primary, Wright, George W., primary, Zhao, Hong, primary, Yang, Yandan, primary, Xu, Weihong, primary, Rosenwald, Andreas, primary, Ott, German, primary, Gascoyne, Randy D., primary, Connors, Joseph M., primary, Rimsza, Lisa M., primary, Campo, Elias, primary, Jaffe, Elaine S., primary, Delabie, Jan, primary, Smeland, Erlend B., primary, Braziel, Rita M., primary, Tubbs, Raymond R., primary, Cook, James R., primary, Weisenburger, Dennis D., primary, Chan, Wing C., primary, Wiestner, Adrian, primary, Kruhlak, Michael J., primary, Iwai, Kazuhiro, primary, Bernal, Federico, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Methods and Figures from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

Author

Ennishi, Daisuke, primary, Takata, Katsuyoshi, primary, Béguelin, Wendy, primary, Duns, Gerben, primary, Mottok, Anja, primary, Farinha, Pedro, primary, Bashashati, Ali, primary, Saberi, Saeed, primary, Boyle, Merrill, primary, Meissner, Barbara, primary, Ben-Neriah, Susana, primary, Woolcock, Bruce W., primary, Telenius, Adèle, primary, Lai, Daniel, primary, Teater, Matt, primary, Kridel, Robert, primary, Savage, Kerry J., primary, Sehn, Laurie H., primary, Morin, Ryan D., primary, Marra, Marco A., primary, Shah, Sohrab P., primary, Connors, Joseph M., primary, Gascoyne, Randy D., primary, Scott, David W., primary, Melnick, Ari M., primary, and Steidl, Christian, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table S10 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

Author

Ennishi, Daisuke, primary, Takata, Katsuyoshi, primary, Béguelin, Wendy, primary, Duns, Gerben, primary, Mottok, Anja, primary, Farinha, Pedro, primary, Bashashati, Ali, primary, Saberi, Saeed, primary, Boyle, Merrill, primary, Meissner, Barbara, primary, Ben-Neriah, Susana, primary, Woolcock, Bruce W., primary, Telenius, Adèle, primary, Lai, Daniel, primary, Teater, Matt, primary, Kridel, Robert, primary, Savage, Kerry J., primary, Sehn, Laurie H., primary, Morin, Ryan D., primary, Marra, Marco A., primary, Shah, Sohrab P., primary, Connors, Joseph M., primary, Gascoyne, Randy D., primary, Scott, David W., primary, Melnick, Ari M., primary, and Steidl, Christian, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figures S1 - S14 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

Author

Jiang, Yanwen, primary, Ortega-Molina, Ana, primary, Geng, Huimin, primary, Ying, Hsia-Yuan, primary, Hatzi, Katerina, primary, Parsa, Sara, primary, McNally, Dylan, primary, Wang, Ling, primary, Doane, Ashley S., primary, Agirre, Xabier, primary, Teater, Matt, primary, Meydan, Cem, primary, Li, Zhuoning, primary, Poloway, David, primary, Wang, Shenqiu, primary, Ennishi, Daisuke, primary, Scott, David W., primary, Stengel, Kristy R., primary, Kranz, Janice E., primary, Holson, Edward, primary, Sharma, Sneh, primary, Young, James W., primary, Chu, Chi-Shuen, primary, Roeder, Robert G., primary, Shaknovich, Rita, primary, Hiebert, Scott W., primary, Gascoyne, Randy D., primary, Tam, Wayne, primary, Elemento, Olivier, primary, Wendel, Hans-Guido, primary, and Melnick, Ari M., primary

Published
2023
Full Text
View/download PDF

42. Table S2 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 1 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

Author

Yang, Yibin, primary, Schmitz, Roland, primary, Mitala, Joseph, primary, Whiting, Amanda, primary, Xiao, Wenming, primary, Ceribelli, Michele, primary, Wright, George W., primary, Zhao, Hong, primary, Yang, Yandan, primary, Xu, Weihong, primary, Rosenwald, Andreas, primary, Ott, German, primary, Gascoyne, Randy D., primary, Connors, Joseph M., primary, Rimsza, Lisa M., primary, Campo, Elias, primary, Jaffe, Elaine S., primary, Delabie, Jan, primary, Smeland, Erlend B., primary, Braziel, Rita M., primary, Tubbs, Raymond R., primary, Cook, James R., primary, Weisenburger, Dennis D., primary, Chan, Wing C., primary, Wiestner, Adrian, primary, Kruhlak, Michael J., primary, Iwai, Kazuhiro, primary, Bernal, Federico, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

44. Data from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

Author

Yang, Yibin, primary, Schmitz, Roland, primary, Mitala, Joseph, primary, Whiting, Amanda, primary, Xiao, Wenming, primary, Ceribelli, Michele, primary, Wright, George W., primary, Zhao, Hong, primary, Yang, Yandan, primary, Xu, Weihong, primary, Rosenwald, Andreas, primary, Ott, German, primary, Gascoyne, Randy D., primary, Connors, Joseph M., primary, Rimsza, Lisa M., primary, Campo, Elias, primary, Jaffe, Elaine S., primary, Delabie, Jan, primary, Smeland, Erlend B., primary, Braziel, Rita M., primary, Tubbs, Raymond R., primary, Cook, James R., primary, Weisenburger, Dennis D., primary, Chan, Wing C., primary, Wiestner, Adrian, primary, Kruhlak, Michael J., primary, Iwai, Kazuhiro, primary, Bernal, Federico, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

45. Data from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Fig. 1 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

Author

Yang, Yibin, primary, Schmitz, Roland, primary, Mitala, Joseph, primary, Whiting, Amanda, primary, Xiao, Wenming, primary, Ceribelli, Michele, primary, Wright, George W., primary, Zhao, Hong, primary, Yang, Yandan, primary, Xu, Weihong, primary, Rosenwald, Andreas, primary, Ott, German, primary, Gascoyne, Randy D., primary, Connors, Joseph M., primary, Rimsza, Lisa M., primary, Campo, Elias, primary, Jaffe, Elaine S., primary, Delabie, Jan, primary, Smeland, Erlend B., primary, Braziel, Rita M., primary, Tubbs, Raymond R., primary, Cook, James R., primary, Weisenburger, Dennis D., primary, Chan, Wing C., primary, Wiestner, Adrian, primary, Kruhlak, Michael J., primary, Iwai, Kazuhiro, primary, Bernal, Federico, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Methods from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

50. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact

Author

Ennishi, Daisuke, Mottok, Anja, Ben-Neriah, Susana, Shulha, Hennady P., Farinha, Pedro, Chan, Fong Chun, Meissner, Barbara, Boyle, Merrill, Hother, Christoffer, Kridel, Robert, Lai, Daniel, Saberi, Saeed, Bashashati, Ali, Shah, Sohrab P., Morin, Ryan D., Marra, Marco A., Savage, Kerry J., Sehn, Laurie H., Steidl, Christian, Connors, Joseph M., Gascoyne, Randy D., and Scott, David W.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results